Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ANDRX (ADRX) -- Ignore unavailable to you. Want to Upgrade?

To: Dave K who wrote (112)	2/18/2000 3:54:00 PM
From: Dave K	Read Replies (1) \| Respond to of 127

David Saks: They are totally different types of companies in the drug industry. Andrx is a specialty house. Exclusively, they do drug delivery, time-release, solid dosage form only. They have numerous products that are on the market, and they have a future of big products that could make their earnings close to $4 a share in the year 2003; and in 2004, maybe close to $6 a share. By comparison, the company has just reported earnings close to $2 a share. So, I see [Andrx] earnings among the most explosive in the drug industry based on their technology of time-released, solid dose drugs that are both generic and proprietary. stockhouse.com